{"name":"Beijing Northland Biotech. Co., Ltd.","slug":"beijing-northland-biotech-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NL003","genericName":"NL003","slug":"nl003","indication":"Advanced solid tumors (Phase 3 development)","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"NL201","genericName":"NL201","slug":"nl201","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"NL003","genericName":"NL003","slug":"nl003","phase":"phase_3","mechanism":"NL003 is a recombinant human IL-2 mutein that selectively activates IL-2 receptor signaling to enhance immune cell proliferation and anti-tumor activity.","indications":["Advanced solid tumors (Phase 3 development)"],"catalyst":""},{"name":"NL201","genericName":"NL201","slug":"nl201","phase":"phase_3","mechanism":"NL201 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-02","type":"pipeline","source":"GuruFocus","summary":"Stock List: Research Stocks from Around the World - GuruFocus","headline":"Stock List: Research Stocks from Around the World","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxQX1VuWmh5WWpPdWtKbXdKTVN0U2dlSXpDSmpRQ1pWR0l4SlRjN0dKamhCd0w5Zmk5V0pXSE4wOU8xRXNlQnY0cUpnalB0ejdfTE4tSmlPelVEQTdnZGFaemlWYXdZZmJzUndieUFGTmdVT3BhYWdMaVV2RU1iQ0tkUDRyb01hMWZqcDNKa0EzLXd6LVhDeDNlR2FlUThQVTc4TWFKdU1OSU1GUGpfZjBCRmZwMmhYMmJHMl9lMnJOdVpwWEZIaUFQT3RTZHJBSmtRTW5SRTlXa24yejlRQlozcklNWV9zS1hQQmRBZDJRdVRzZTdZVGpVMnZQaFZ6M0pDc1NDOHIycTQ5QQ?oc=5","date":"2023-09-26","type":"pipeline","source":"PR Newswire","summary":"Atherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsight - PR Newswire","headline":"Atherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxOak05RFNibTVMNU5ZSDR2RERnVkVDNHZEWXlMUE1oeWZHbWdqeXJsR2ZyV0ZsMmxtSXJqODBxMEVtR0dYSzBBTnMtNE02Ml9sZ1RFYXF3NWU4ek1TSTVBMHhMLVJ4d29KZzlETFVueHNZVnY1SENUazZIb1BGbER5ZGlnc0RWWllZSjA0VjJwS2MydjNNLUI2OUxlcW5IMjJWcjBFU0pENTY4ZjVaVzIxb2tubC1PVG1FejFpWWxXRGo0RlBBejN6ODBtLWlTUzZvQ1RvY1RyVUZMMmV4NTdCbTl2NXdPSkVHOFR6RThaUHk1eDh3NFRrZ2lsTVN6S0hIbUg1MDhPVHZ6d040UDZyakRZYWY1eDNORHQ3YmJsY25paGtVamJOY3dvVmxDb0hrTWxj?oc=5","date":"2023-08-02","type":"pipeline","source":"PR Newswire","summary":"Atherosclerosis Market to Witness Growth by 2032, Estimates DelveInsight | Leading Companies - CSL Behring, Novartis, Merck, Amgen, Ionis , BioMarin, AstraZeneca - PR Newswire","headline":"Atherosclerosis Market to Witness Growth by 2032, Estimates DelveInsight | Leading Companies - CSL Behring, Novartis, Me","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}